Having just launched the IL-13 inhibitor lebrikizumab in Europe for atopic dermatitis, Almirall SAis now looking at IL-21 as a possible new pathway to treat a range of dermatological diseases after inking a licensing deal with Novo Nordisk A/S.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?